The resulting tumour-immune dysfunction and exclusion (TIDE) score is one of the first multigene signatures that predicts the outcome of cancer patients treated with first-line anti-PD-1 or anti-CTLA-4, instead of using single biomarkers like PD-L1 or tumour mutation load [79]. Here, CD274 is linked to neoplasm.